CL2019000935A1 - Composición farmacéutica, métodos para tratamiento y usos de la misma. - Google Patents

Composición farmacéutica, métodos para tratamiento y usos de la misma.

Info

Publication number
CL2019000935A1
CL2019000935A1 CL2019000935A CL2019000935A CL2019000935A1 CL 2019000935 A1 CL2019000935 A1 CL 2019000935A1 CL 2019000935 A CL2019000935 A CL 2019000935A CL 2019000935 A CL2019000935 A CL 2019000935A CL 2019000935 A1 CL2019000935 A1 CL 2019000935A1
Authority
CL
Chile
Prior art keywords
treatment
methods
pharmaceutical composition
inhibitor
delay
Prior art date
Application number
CL2019000935A
Other languages
English (en)
Spanish (es)
Inventor
Joerg Rippmann
Thomas Klein
Michael Mark
Eric Williams Mayoux
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2019000935A1 publication Critical patent/CL2019000935A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2019000935A 2016-10-19 2019-04-08 Composición farmacéutica, métodos para tratamiento y usos de la misma. CL2019000935A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16194572 2016-10-19

Publications (1)

Publication Number Publication Date
CL2019000935A1 true CL2019000935A1 (es) 2019-08-09

Family

ID=57178303

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000935A CL2019000935A1 (es) 2016-10-19 2019-04-08 Composición farmacéutica, métodos para tratamiento y usos de la misma.

Country Status (14)

Country Link
US (1) US20210212968A1 (enExample)
EP (1) EP3528800A1 (enExample)
JP (1) JP2019531320A (enExample)
KR (1) KR20190070956A (enExample)
CN (1) CN109843279A (enExample)
AU (1) AU2017344882A1 (enExample)
BR (1) BR112019005930A2 (enExample)
CA (1) CA3041169A1 (enExample)
CL (1) CL2019000935A1 (enExample)
EA (1) EA201990951A1 (enExample)
IL (1) IL265989A (enExample)
MX (1) MX2019004549A (enExample)
PH (1) PH12019500845A1 (enExample)
WO (1) WO2018073154A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190110736A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20190110740A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
SG11202103062UA (en) * 2018-09-28 2021-04-29 Acucela Inc Inhibitors of vap-1
MX2021003731A (es) 2018-09-28 2021-08-05 Acucela Inc Inhibidores de vap-1.
JP7414230B2 (ja) * 2018-11-09 2024-01-16 国立大学法人 琉球大学 抗血液悪性腫瘍薬
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
TWI835945B (zh) * 2018-12-14 2024-03-21 南韓商柳韓洋行股份有限公司 3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物
TW202039486A (zh) * 2018-12-14 2020-11-01 南韓商柳韓洋行股份有限公司 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
CN114375193B (zh) 2019-09-12 2024-05-14 拓臻制药公司 甲状腺激素受体β激动剂化合物
EP4051669A4 (en) 2019-10-29 2023-12-13 Eccogene (Shanghai) Co., Ltd. SSAO INHIBITORS AND THEIR USE
CN115666577A (zh) * 2020-03-25 2023-01-31 拓臻股份有限公司 呼吸道病症的治疗
KR20230023642A (ko) * 2020-05-13 2023-02-17 테른스 파마슈티칼스, 인크. 간 장애의 조합 치료
CN113893256A (zh) * 2020-07-06 2022-01-07 诺未科技（北京）有限公司 化合物或其可药用盐、二聚体或三聚体在制备治疗癌症的药物中的应用
AU2021332217A1 (en) 2020-08-25 2023-05-11 Eli Lilly And Company Polymorphs of an ssao inhibitor
US20240148767A1 (en) * 2021-03-04 2024-05-09 The Governors Of The University Of Alberta The use of empagliflozin for the treatment of ulcerative colitis and crohn's disease
JP2024543419A (ja) * 2021-11-11 2024-11-21 ターンズ・ファーマシューティカルズ・インコーポレイテッド Ｓｓａｏ阻害剤による肝障害の治療
EP4429665A1 (en) * 2021-11-11 2024-09-18 Terns Pharmaceuticals, Inc. Combination of a ssao inhibitor and thr-beta agonist for use in the treatment of liver disorders

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1145635C (zh) 1999-08-31 2004-04-14 橘生药品工业株式会社 吡喃葡糖氧基吡唑衍生物、含该衍生物的药物组合物及其制备中的中间体
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
CA2429833A1 (en) 2000-11-30 2002-06-06 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
HU228915B1 (en) 2000-12-28 2013-06-28 Kissei Pharmaceutical Glucopyranosyloxypyrazole derivatives and use thereof
KR100945455B1 (ko) 2002-03-22 2010-03-05 깃세이 야쿠힌 고교 가부시키가이샤 글루코피라노실옥시벤질 벤젠 유도체의 결정
DE10231370B4 (de) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
ES2567571T3 (es) 2003-03-14 2016-04-25 Astellas Pharma Inc. Derivados de C-glucósido y sales de los mismos
EP2514756B1 (en) 2003-08-01 2014-12-17 Mitsubishi Tanabe Pharma Corporation Novel compounds having inhibitory activity against sodium-dependant glucose transporter
PL1730131T3 (pl) 2004-03-16 2012-10-31 Boehringer Ingelheim Int Glukopiranozylo-podstawione pochodne benzenu, środki lecznicze zawierające te związki, ich zastosowanie i sposób ich wytwarzania
TW200637839A (en) 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
ATE517099T1 (de) 2006-02-15 2011-08-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte benzonitril-derivate,pharmazeutische zusammensetzungen mit derartigen verbindungen, ihre verwendung und herstellungsverfahren dafür
WO2007140191A2 (en) 2006-05-23 2007-12-06 Theracos, Inc. Glucose transport inhibitors and methods of use
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
US7846945B2 (en) 2007-03-08 2010-12-07 Lexicon Pharmaceuticals, Inc. Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
TW200904405A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
WO2009014970A1 (en) 2007-07-26 2009-01-29 Lexicon Pharmaceuticals, Inc. Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
HUE035130T2 (en) 2007-09-10 2018-05-02 Janssen Pharmaceutica Nv A method for preparing compounds useful as SGLT inhibitors
WO2009066152A2 (en) 2007-11-21 2009-05-28 Pharmaxis Ltd. Haloallylamine inhibitors of ssao/vap-1 and uses therefor
TW201011043A (en) 2008-06-20 2010-03-16 Chugai Pharmaceutical Co Ltd Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives
TWI472521B (zh) 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法
CN102149717B (zh) 2008-08-28 2014-05-14 辉瑞大药厂 二氧杂-双环[3.2.1]辛烷-2，3，4-三醇衍生物
FI2395968T3 (fi) 2009-02-13 2024-02-27 Boehringer Ingelheim Int Glukopyranosylidifenylimetaanijohdannaisia sisältävä farmaseuttinen koostumus, niiden farmaseuttinen annostusmuoto, niiden valmistusmenetelmä ja niiden käyttö potilaan glukemiasäädön parantamiseksi
TW201103534A (en) 2009-04-16 2011-02-01 Taisho Pharmaceutical Co Ltd Pharmaceutical compositions
CA2775962C (en) 2009-09-30 2017-09-05 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
EA020798B1 (ru) 2009-09-30 2015-01-30 Бёрингер Ингельхайм Интернациональ Гмбх СПОСОБ ПОЛУЧЕНИЯ КРИСТАЛЛИЧЕСКОЙ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА
CN104520268B (zh) * 2012-05-02 2017-05-24 勃林格殷格翰国际有限公司 Ssao的取代的3‑卤代烯丙基胺抑制剂及其用途

Also Published As

Publication number Publication date
CA3041169A1 (en) 2018-04-26
CN109843279A (zh) 2019-06-04
IL265989A (en) 2019-06-30
BR112019005930A2 (pt) 2019-06-11
PH12019500845A1 (en) 2019-12-02
US20210212968A1 (en) 2021-07-15
EP3528800A1 (en) 2019-08-28
WO2018073154A1 (en) 2018-04-26
EA201990951A1 (ru) 2019-11-29
JP2019531320A (ja) 2019-10-31
KR20190070956A (ko) 2019-06-21
AU2017344882A1 (en) 2019-03-28
MX2019004549A (es) 2019-06-12

Similar Documents

Publication Publication Date Title
CL2019000935A1 (es) Composición farmacéutica, métodos para tratamiento y usos de la misma.
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CO2019013707A2 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson
EP3735976A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
PH12019500494A1 (en) Formulations of (r)-2-amino-3-phenylpropyl carbamate
MX383164B (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
MX2018004515A (es) Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
MX2019000965A (es) Composiciones y metodos para inihibir la masp-3 para el tratamiento de diferentes enfermedades y trastornos.
MX2017016655A (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
MX381069B (es) Profármacos de carbidopa y l-dopa y métodos de uso.
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
MX389207B (es) Composiciones de nicotinamida ribósido y pteroestilbeno y métodos para el tratamiento de trastornos de la piel.
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
CL2019003670A1 (es) Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta.
MX2016011667A (es) Composiciones topicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad.
MX2023010501A (es) Profarmacos de dantroleno y metodos de su uso.
MX2018005825A (es) Celulas inmunes modificadas y usos de las mismas.
MX2021011334A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX374705B (es) Composiciones que comprenden anakinra.
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
MX2018007128A (es) Composiciones para barnices dentales y metodos para su elaboracion y uso.
EP3881845A3 (en) Combination of trazodone and gabapentin for the treatment of pain
MX384394B (es) Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol